vTv Therapeutics (VTVT)
Develops oral small molecules for diabetes, centered on cadisegliatin alongside insulin.
Something off on this page? Send us feedback.
Develops oral small-molecule treatments for diabetes and other chronic diseases, centered on cadisegliatin, an adjunct-to-insulin candidate for type 1 diabetes. The clinical-stage business has no marketed drug sales and derives revenue primarily from collaboration and license arrangements.
Develops oral small-molecule treatments for diabetes and other chronic diseases, with cadisegliatin as its central program. The liver-selective glucokinase activator is being studied alongside insulin for type 1 diabetes in the U.S. Phase 3 CATT1 trial.
The business is concentrated around clinical development rather than marketed medicines: it has not generated drug-sales revenue, and collaboration and license arrangements have supplied revenue. HPP737 is licensed worldwide to Newsoara Biopharma for development and commercialization.
Progress depends on CATT1 enrollment, clinical outcomes, regulatory review, and potential approval. FDA previously placed the program on clinical hold before lifting it after the company's response.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Target | Target: $47 | Target: $42 |
| Jun 30, 2026 | Rodman & Renshaw | Initiate | Rating: — | |
| Jan 27, 2026 | BTIG | Reiterate | Rating: —Target: — | Target: $49 |
| Jan 22, 2026 | Roth Capital | Target | Target: — | Target: $58 |
| Dec 19, 2025 | H.C. Wainwright | Target | Target: — | Target: $47 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $86.6M · Total debt $0 · Total assets $87.6M · Shareholders' equity $78.6M
- Revenue
- $0
- Operating income
- −$13.9M
- Net income
- −$13.1M
No dividends on record.
| Institutions | 40.65% | 1.61M shares | |
|---|---|---|---|
| 44 holders · as of Jun 30, 2026 | |||
| Insiders | 28.88% | 1.14M shares | |
| 4 holders · as of Feb 18, 2026 | |||
| Strategic holders | 5.23% | 206.8K shares | |
| 1 holder · as of Dec 6, 2024 | |||
| Other | 25.24% | 998.0K shares | |
| remainder | |||
3.95M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (3.95M in the company's Sep 23, 2026 report, 2.62M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Srinivas Akkaraju1Insiderdirector | 10.22% | 403,942 A | filed Dec 9, 2025 |
Paul J. SekhriInsiderdirector, officer: Pres, CEO and Exec Chairperson | 9.92% | 392,212 A | filed Feb 18, 2026 |
Invus Public Equities, L.P.Insider | 8.75% | 345,926 | filed Nov 12, 2025 |
Samsara Biocapital, LLCInstitution | 7.55% | 298,496 A | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 6.83% | 269,874 A | as of Jun 30, 2026 |
- Srinivas Akkaraju's transaction reports restate only vehicles that traded; the 2025 ownership statement (403.9K) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- MiniMed Group
Integrated automated insulin delivery for T1D glycemic management
- Insulet
Tubeless automated insulin delivery for T1D control and low protection
- Tandem Diabetes Care
Predictive automated insulin delivery for T1D low and high control
- Beta Bionics
Autonomous insulin dosing for T1D glycemic management
- Vertex Pharmaceuticals
Investigational islet-cell therapy for severe T1D hypoglycemia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| vTv Therapeutics | $30.51 | −1.91% | $81.4M | — | — | 2.2 | — |
| MiniMed Group | $20.72 | −2.26% | $5.95B | — | 36.0 | 1.8 | — |
| Insulet | $136.94 | −1.75% | $9.65B | 26.1 | 19.9 | 3.2 | +23.5% |
| Tandem Diabetes Care | $16.68 | −4.70% | $1.20B | — | — | 1.2 | +5.8% |
| Beta Bionics | $22.29 | −2.26% | $1.03B | — | — | 8.6 | +37.8% |
| Vertex Pharmaceuticals | $509.92 | −0.98% | $130.71B | 30.0 | 26.5 | 10.4 | +12.5% |
| Median | 28.0 | 26.5 | 3.2 | +18.0% |